$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416116648 Filed on August 04, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$746.0K	$1.150M
YoY Change	-35.13%	170018.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$820.0K	$1.820M
YoY Change	-54.95%	-24.79%
% of Gross Profit
Research & Development	$1.382M	$1.223M
YoY Change	13.0%	-48.47%
% of Gross Profit
Depreciation & Amortization	$40.44K	$36.69K
YoY Change	10.22%	1.32%
% of Gross Profit
Operating Expenses	$2.348M	$3.114M
YoY Change	-24.6%	-35.5%
Operating Profit	-$1.602M	-$1.965M
YoY Change	-18.46%	67.96%
Interest Expense	$9.618K	$13.28K
YoY Change	-27.57%	-76.52%
% of Operating Profit
Other Income/Expense, Net	-$14.88K	-$365.0K
YoY Change	-95.92%	-150.41%
Pretax Income	-$1.617M	-$2.330M
YoY Change	-30.59%	422.64%
Income Tax	$15.44K	$11.07K
% Of Pretax Income
Net Earnings	-$1.617M	-$2.341M
YoY Change	-30.92%	433.1%
Net Earnings / Revenue	-216.78%	-203.56%
Basic Earnings Per Share	$0.12	-$0.04
Diluted Earnings Per Share	$0.12	-$0.04
COMMON SHARES
Basic Shares Outstanding	64.74M shares	63.75M shares
Diluted Shares Outstanding	65.21M shares	63.75M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.20M	$18.40M
YoY Change	26.09%	62.83%
Cash & Equivalents	$23.16M	$18.41M
Short-Term Investments	$6.400M	$6.400M
Other Short-Term Assets	$400.0K	$300.0K
YoY Change	33.33%	-50.0%
Inventory
Prepaid Expenses
Receivables	$1.800M	$1.200M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$25.40M	$19.91M
YoY Change	27.6%	60.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$183.7K	$308.3K
YoY Change	-40.41%	-20.25%
Goodwill	$2.348M	$2.348M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$53.38K
YoY Change	-100.0%	-2.99%
Total Long-Term Assets	$2.532M	$2.710M
YoY Change	-6.57%	-2.86%
TOTAL ASSETS
Total Short-Term Assets	$25.40M	$19.91M
Total Long-Term Assets	$2.532M	$2.710M
Total Assets	$27.93M	$22.62M
YoY Change	23.5%	48.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$711.1K	$208.5K
YoY Change	241.13%	-52.34%
Accrued Expenses	$1.700M	$2.700M
YoY Change	-37.04%	92.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$200.0K
YoY Change	-100.0%
Long-Term Debt Due		$249.5K
YoY Change		-75.05%
Total Short-Term Liabilities	$3.269M	$3.300M
YoY Change	-0.95%	16.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$411.6K	$900.0K
YoY Change	-54.26%	57.11%
Total Long-Term Liabilities	$411.6K	$900.0K
YoY Change	-54.26%	10.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.269M	$3.300M
Total Long-Term Liabilities	$411.6K	$900.0K
Total Liabilities	$3.680M	$4.300M
YoY Change	-14.41%	-1.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$216.9M
YoY Change
Common Stock	$6.479K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.25M	$18.30M
YoY Change
Total Liabilities & Shareholders Equity	$27.93M	$22.60M
YoY Change	23.59%	48.45%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$1.617M	-$2.341M
YoY Change	-30.92%	433.1%
Depreciation, Depletion And Amortization	$40.44K	$36.69K
YoY Change	10.22%	1.32%
Cash From Operating Activities	$8.540M	$2.650M
YoY Change	222.26%	-590.74%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$20.00K
YoY Change	50.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$30.00K	-$20.00K
YoY Change	50.0%	-50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	420.0K	50.00K
YoY Change	740.0%	-97.83%
NET CHANGE
Cash From Operating Activities	8.540M	2.650M
Cash From Investing Activities	-30.00K	-20.00K
Cash From Financing Activities	420.0K	50.00K
Net Change In Cash	8.930M	2.680M
YoY Change	233.21%	55.81%
FREE CASH FLOW
Cash From Operating Activities	$8.540M	$2.650M
Capital Expenditures	-$30.00K	-$20.00K
Free Cash Flow	$8.570M	$2.670M
YoY Change	220.97%	-634.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23157883	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15569813	USD
CY2016Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	1024374	USD
CY2015Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	511994	USD
CY2016Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	797913	USD
CY2015Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	963345	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	418636	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181714	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	25398806	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	17226866	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	183695	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	233694	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	53384	USD
CY2016Q2	us-gaap	Goodwill Goodwill	2348453	USD
CY2015Q4	us-gaap	Goodwill Goodwill	2348453	USD
CY2016Q2	us-gaap	Assets Assets	27930954	USD
CY2015Q4	us-gaap	Assets Assets	19862397	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	711106	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	521122	USD
CY2016Q2	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1510003	USD
CY2015Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1248708	USD
CY2016Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	237125	USD
CY2015Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	381950	USD
CY2016Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11588	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11250	USD
CY2016Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	798788	USD
CY2015Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	16411	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3268610	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2179441	USD
CY2016Q2	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	0	USD
CY2015Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	108641	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	411640	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	433407	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	491791	USD
CY2016Q2	us-gaap	Liabilities Liabilities	3680250	USD
CY2015Q4	us-gaap	Liabilities Liabilities	3213280	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	6479	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	6438	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241150682	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	24250704	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	16649117	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27930954	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19862397	USD
CY2016Q2	us-gaap	Contracts Revenue ContractsRevenue	2111254	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	1149570	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1143182	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1222527	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64571108	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63691214	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64917267	shares
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1435381	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1819241	USD
CY2016Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2015Q2	us-gaap	Restructuring Charges RestructuringCharges	35982	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-364997	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15436	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11068	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	8044474	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2340932	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64737820	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63745834	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65206075	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63745834	shares
	us-gaap	Contracts Revenue ContractsRevenue	3116948	USD
	us-gaap	Contracts Revenue ContractsRevenue	8218316	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2172313	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2836154	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2628679	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4015361	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	2096791	USD
	us-gaap	Depreciation Depreciation	78136	USD
	us-gaap	Depreciation Depreciation	73793	USD
	us-gaap	Operating Expenses OperatingExpenses	4879128	USD
	us-gaap	Operating Expenses OperatingExpenses	9022099	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1762180	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-803783	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	428	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-38604	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-290586	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	217630	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5741	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7285	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-42881	USD
	us-gaap	Net Income Loss NetIncomeLoss	6817568	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63691214	shares
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8044474	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-507744	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1911	USD
CY2016Q2	us-gaap	Depreciation Depreciation	40435	USD
CY2015Q2	us-gaap	Depreciation Depreciation	36687	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	2618998	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	3114437	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1964867	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1478	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-13279	USD
CY2016Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-330484	USD
CY2015Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-120615	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1622	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8567654	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	8059910	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2329864	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2113150	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	336	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	404271	shares
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-48677	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	348720	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	333231	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	348720	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-182940	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-263443	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	790617	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	213067	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	647233	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	7184295	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-60055	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28137	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56277	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	687	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7600	USD
	pip	Percentage Of Share Based Compensation Forfeitures PercentageOfShareBasedCompensationForfeitures	0.12	pure
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-27450	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	30873	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	9977	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	687	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-165432	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	492754	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	236922	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	127433	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	189984	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-499998	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	435299	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-123453	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4074	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	673	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7588070	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-231512	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18643351	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18411839	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	21452	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	512380	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	276979	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	436188	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	376545	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-889	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2016Q2	pip	Proceeds From Interest On Legal Settlement Claims ProceedsFromInterestOnLegalSettlementClaims	3900000	USD
CY2017Q2	pip	Total Value Of Contracts With Government TotalValueOfContractsWithGovernment	28100000	USD
CY2014Q3	pip	Initial Fund Value InitialFundValue	5200000	USD
CY2014Q3	pip	Additional Fund Value AdditionalFundValue	6000000	USD
CY2016Q2	pip	Billed And Unbilled Accounts Receivable Net BilledAndUnbilledAccountsReceivableNet	1800000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	490591	USD
	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	131822	USD
	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	121644	USD
CY2016Q2	us-gaap	Restructuring Reserve RestructuringReserve	237125	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	166795	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	133604	USD
	pip	Share Based Compensation Extension Of Exercise Period ShareBasedCompensationExtensionOfExercisePeriod	75000	USD
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1000000	USD
	pip	Share Based Compensation Reversal From Stock Option Forfeitures ShareBasedCompensationReversalFromStockOptionForfeitures	129000	USD
	pip	Share Based Compensation Reversal Net ShareBasedCompensationReversalNet	53741	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12000	shares
	pip	Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod	117500	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7200000	shares
CY2015Q4	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	205000000	USD
	pip	Percentage Of Common Stock Delivered PercentageOfCommonStockDelivered	1	pure
CY2015Q1	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	194600000	USD
CY2015Q1	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	113100000	USD
CY2015Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	81500000	USD
CY2015Q4	us-gaap	Government Contract Receivable Progess Payments Offset GovernmentContractReceivableProgessPaymentsOffset	5800000	USD
	pip	Operating Lease Term OperatingLeaseTerm	P10Y
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	428294	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	356911	USD
CY2015Q4	pip	Beneficial Ownership Percentage Held By Affiliates BeneficialOwnershipPercentageHeldByAffiliates	0.0499	pure
CY2015Q4	pip	Additional Amount To Declare Stockholder As Acquiring Person Percentage AdditionalAmountToDeclareStockholderAsAcquiringPersonPercentage	0.005	pure
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1051358	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1922781	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	186957	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	PIP
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65591840	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	pip	Otherincome Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherincomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	0	USD
CY2015Q2	pip	Otherincome Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherincomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	229192	USD
	pip	Otherincome Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherincomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	0	USD
	pip	Otherincome Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherincomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	229192	USD
CY2016Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	8895038	USD
CY2015Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	8895038	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-229192	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-229192	USD
CY2016Q3	pip	Distribution Rate Of Cash Proceeds To Stock Holders DistributionRateOfCashProceedsToStockHolders	0.9	pure
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: italic 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: italic 10pt Times New Roman, Times, Serif" align="justify">Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200000	shares
CY2016Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20000	USD
CY2015Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000	USD
CY2016Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	798788	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200000	shares
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	785205	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	341121	shares
CY2016Q2	us-gaap	Government Contract Receivable Progess Payments Offset GovernmentContractReceivableProgessPaymentsOffset	800000	USD
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64785846	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64785846	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64382086	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64382086	shares
	pip	Percentage Of Share Based Compensation Forfeitures PercentageOfShareBasedCompensationForfeitures	0.12	pure
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	100000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216906457	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223724025	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-53384	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2016Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	24004	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	22288	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8020470	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6795280	USD
CY2016Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-172	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-118	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	8020642	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6795398	USD
CY2016Q2	pip	Incremental Common Shares Attributable To Dilutive Effect Of Calloptions IncrementalCommonSharesAttributableToDilutiveEffectOfCalloptions	468256	shares
	pip	Incremental Common Shares Attributable To Dilutive Effect Of Calloptions IncrementalCommonSharesAttributableToDilutiveEffectOfCalloptions	346159	shares
CY2016Q2	pip	Proceeds From Interest On Legal Settlement Claims ProceedsFromInterestOnLegalSettlementClaims	3900000	USD
CY2016Q2	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	5000000	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7200000	shares

Files In Submission

Name	View Source	Status
0001144204-16-116648-index-headers.html	Edgar Link	pending
0001144204-16-116648-index.html	Edgar Link	pending
0001144204-16-116648.txt	Edgar Link	pending
0001144204-16-116648-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pip-20160630.xml	Edgar Link	completed
pip-20160630.xsd	Edgar Link	pending
pip-20160630_cal.xml	Edgar Link	unprocessable
pip-20160630_def.xml	Edgar Link	unprocessable
pip-20160630_lab.xml	Edgar Link	unprocessable
pip-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v444808_10q.htm	Edgar Link	pending
v444808_ex31-1.htm	Edgar Link	pending
v444808_ex31-2.htm	Edgar Link	pending
v444808_ex32-1.htm	Edgar Link	pending
v444808_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2016 Q2 Form 10-Q Financial Statement

#000114420416116648 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2016 Q2 Form 10-Q Financial Statement

#000114420416116648 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt